Yesterday, the Federal Reserve walked a thin line well; they left policy unchanged and reaffirmed their “do whatever it takes” narrative.

It's Fed Day and the FOMC is expected to leave policy unchanged. Markets will be looking for Powell to reaffirm the Fed’s “do whatever it takes” narrative in order to bring the U.S. economy back from the depths of the pandemic. 

U.S. benchmarks finished higher yesterday after strong technical support held. This morning we look to a deluge of corporate earnings, less so for their 2nd quarter results and more for their outlook.

U.S. benchmarks settled-in after surging overnight upon positive Covid-19 vaccine news. The market often finds a silver lining to perform given this ultra-liquid zero interest rate policy world.

Despite unenthusiastic results from tech behemoth and cloud bellwether Microsoft, Tesla’s headline numbers are keeping the risk-environment buoyant.

U.S. benchmarks surged from Monday’s opening bell into the second half of yesterday. The S&P 500 achieved the highest level since February 24 and the Nasdaq-100 again notched 11,000 but failed to set a new high by half a point.

U.S. benchmarks are set to continue their push higher led by tailwinds from recovery fund stimulus and strong earnings from IBM.

Stimulus is in the air and buoying U.S. benchmarks from their overnight lows. With a light economic calendar this week, the focus will be earnings.

U.S. benchmarks settled-in after surging overnight upon positive Covid-19 vaccine news. The market often finds a silver lining to perform given this ultra-liquid zero interest rate policy world.

Moderna published the results of their Phase 1 trial late yesterday, it showed an immune response in all 45 patients with only minor side effects. Amid these bullish tailwinds, there are now expectations of good news to be announced surrounding Oxford University’s Covid-19 vaccine candidate backed by AstraZeneca.